Lonza Group AG Lonza Group AG

Lonza Group AG

LONN

Kedudukan dalam Saham #447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Harga Saham
$766.95
Modal Pasaran
$53.57B
Perubahan (1 hari)
1.35%
Perubahan (1 tahun)
9.01%
Negara
CH
Perdagangan Lonza Group AG (LONN)

Kategori

Healthcare
Nisbah P/E bagi Lonza Group AG (LONN)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Lonza Group AG, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Lonza Group AG dari 2004 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2025 -136.84 -328.07%
2024 60.00 50.64%
2023 39.83 43.89%
2022 27.68 44.10%
2021 19.21 -60.56%
2020 48.70 20.01%
2019 40.58 19.47%
2018 33.97 37.99%
2017 24.62 -14.17%
2016 28.68 -0.14%
2015 28.72 25.50%
2014 22.89 -51.23%
2013 46.92 225.35%
2012 14.42 -22.50%
2011 18.61 34.53%
2010 13.83 -40.66%
2009 23.31 89.92%
2008 12.27 -49.05%
2007 24.09 -7.06%
2006 25.92 27.93%
2005 20.26 -7.79%
2004 21.97 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.78 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -28.36 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -25.99 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.22 -
NL
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 17.49 -
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.